Coegin Pharma is a Swedish biotechnology company developing cutting-edge peptide-based innovations for hair growth and skin pigmentation. Having transitioned from traditional drug development, we now focus exclusively on premium cosmetic peptides – combining scientific insight with commercial drive to bring innovative solutions to market.
This strategic shift aligns with our commitment to delivering scientifically backed, effective products within the global longevity megatrend – a movement dedicated to extending and enhancing quality of life. Hair growth is a key part of this trend, with increasing demand for products that combine proven efficacy and safety with a rejuvenating effect. Follicopeptide embodies these qualities and has the potential to set a new industry standard.
“We’re in the midst of a global megatrend where more and more people seek scientifically based solutions to maintain a youthful and vital appearance,” says Jens Eriksson, CEO of Coegin Pharma. “The response we’re receiving confirms Follicopeptide’s potential to be a game changer in hair growth.”
Our Vision
To lead the future of cutting-edge solutions for hair and skin longevity.
Our Mission
To harness biotechnology to develop cosmetic innovations – enabling hair regeneration and enhanced skin vitality for people worldwide.
Innovating with world-class universities
Our innovations are built on cutting-edge research in collaboration with leading universities such as Lund University and the University of Bradford. These partnerships strengthen our scientific foundation and fuel our innovative approach.
Management Team
Our management team consists of three highly skilled professionals with extensive expertise in biotechnology, business development, and commercialisation. They lead Coegin Pharma’s vision and strategy to lead the future of cutting-edge solutions for hair and skin longevity.
Born in 1975
acting CEO since October 2023 and CEO since april 2024 .
Education and experience: Jens Eriksson has a university degree in finance and marketing with additional studies in biomedicine. Jens has been active as CEO of several major retail chains in Sweden such as ELON, Hemmabutikerna, Hemexperten, and most recently Scania's largest private retailer, Arver Lastbilar. Furthermore, Jens has extensive experience in board work and currently works as a senior consultant in strategy, business development and communication. Jens is also an investor with a focus on Swedish biotech. Jens key competencies are in business development, rationalizations, mergers, communication, marketing and HR.
Holdings: Jens Eriksson owns, privately and through the company iEnce Advisor AB, 479,204 shares.
Born 1975
CFO since 2022.
Education and experience: Lars has extensive experience in the entire pharmaceutical value chain, from medical development, commercialization, financial management and accounting as well as general management thanks to his long experience in various senior positions for LEO Pharma A / S, both in Denmark and the USA at vice president level, and as CFO and COO for Pila Pharma AB. His educational background includes Veterinary Medicine Doctor (VMD) at the University of Copenhagen, Denmark, B.Sc. in Business Administration with a focus on financial management and accounting at the University of Southern Denmark, Denmark, and Executive MBA at Henley Business School, United Kingdom.
Holding: Lars Bukhave Rasmussen owns 69,211 shares in Coegin Pharma AB.
Born 1977
CMO since May 2022.
Education and experience: John Zibert is a renowned pharmaceutical researcher and has over 20 years of experience in drug development and digital health research. John's expertise lies in, among other things, skin diseases, cancer, decentralized clinical trials, biomarkers and innovation processes, which have resulted in more than 70 international scientific publications. John has previously held several management positions such as CEO of Studies & Me A/S, Chief Medical Officer at LEO Innovation Lab and Head of Medical Affairs EU5 + at LEO Pharma A/S, and has contributed to drug development and the launch of several drugs. John has a master's degree in human biology from the University of Otago and University of Copenhagen, a PhD in immunology from the Faculty of Medical Sciences, University of Copenhagen and a leadship education from the Danish Armed Forces.
Shareholding: John Zibert owns 59,411 shares in Coegin Pharma through the fully-owned company Future Brain ApS.
Board of Directors
Our Board of Directors consists of seasoned professionals with extensive experience in pharmaceuticals, biotechnology, finance, and clinical research. Their combined expertise supports Coegin Pharma’s strategic direction and governance, ensuring robust oversight as the company advances its vision to lead the future of cutting-edge solutions for hair and skin longevity.
Born in 1962
Board member since May 2023
Chairman of the board since October 2023.
Education and experience: Eva Sjökvist Saers is a licensed pharmacist with a doctorate from Uppsala University. Eva has long and broad experience from research & development and business and operational development from the pharmaceutical industry with various management positions within Astra/AstraZeneca, group management at Apoteket AB and as CEO of the pharmaceutical company APL with over 500 employees and a turnover of SEK 1.4 billion.
Eva Sjökvist Saers is currently active in a number of life science companies - chairman of Dicot AB and board member of Alligator Bioscience AB, Apoex AB, Bluefish Pharmaceuticals AB and Oxcia AB. Eva is chairman of the strategic innovation program Swelife and has previously been chairman of the Apotekarsocieteten and vice chairman of the industry organization SwedenBIO. Previously, Eva has served on the boards of Dilafor AB, Empowered Health AB, IDL Biotech AB, Karo Pharma AB, Recipharm AB and Karolinska Institutet Holding AB.
Holdings: Eva Sjökvist Saers does not own, privately or through a company, any shares in Coegin Pharma AB.
Born in 1975
Board member since May 2023
Chairman of the board May-October 2023.
Education and experience: Jens Eriksson has a university degree in finance and marketing with additional studies in biomedicine. Jens has been active as CEO of several major retail chains in Sweden such as ELON, Hemmabutikerna, Hemexperten, and most recently Scania's largest private retailer, Arver Lastbilar. Furthermore, Jens has extensive experience in board work and currently works as a senior consultant in strategy, business development and communication. Jens is also an investor with a focus on Swedish biotech. Jens key competencies are in business development, rationalizations, mergers, communication, marketing and HR.
Holdings: Jens Eriksson owns, privately and through the company iEnce Advisor AB, 479,204 shares.
Born 1955
Board member since September 2020.
Education and experience: Erlend Skagseth has an MBA degree and 30 years of experience from R&D-based project management and business development as well as 15 years of experience in VC investments at an early stage. Erlend Skagseth is Managing Partner at Sarsia Seed and has participated in several turnarounds and negotiated several international contracts, licenses and exits. Has extensive experience from board work in development and growth companies.
Shareholding: Sarisa Seed AS owns 144,839 shares in Coegin Pharma. Through Mitosis AS, Erlend Skagseth indirectly owns approximately 5 percent of the shares in Sarisa Seed AS.
Born 1958
Boardmember since 2022.
Education and experience: Thoas Fioretos is professor and senior physician at the Department of Clinical Genetics at Lund University. His research focuses on molecular and functional studies of genetic changes in leukemia and how such changes can be used for diagnostic and therapeutic purposes. He has authored more than 130 scientific articles. Thoas Fioretos is one of the founders of Cantargia AB, Qlucore AB and Lead Biologics International AB. Thoas Fioretos is a board member of Cantargia AB, Qlucore AB and Lead Biologics International.
Shareholding: Thoas Fioretos does not own, privately or through companies, any shares in Coegin Pharma.
